French Pharma Stock News

Air France-KLM (ENXTPA:AF) is back in focus after a period in which the share price has moved lower over the week, month and past 3 months, despite a positive 1 year total return. See our latest analysis for Air France-KLM. That recent share price pressure, including a 5.15% 1 day share price return decline and weaker 7 day and 90 day share price returns, contrasts with a 50.18% 1 year total shareholder return. This suggests earlier optimism has cooled and investors are reassessing risk and...

If you are wondering whether Vinci at €116.75 is offering fair value or a margin of safety, you are not alone. This article focuses squarely on what the current price might mean for investors. The stock has seen a 6.0% decline over the last 7 days and a 2.8% decline over the last 30 days, while still showing a 21.6% return over 1 year, 26.5% over 3 years and 67.6% over 5 years. This raises questions about how the recent pullback fits into the longer term picture. Recent news flow around...

In the first quarter of fiscal 2026, Sodexo reported past consolidated revenue of €6,260 million, slightly below the prior year's €6,403 million. Ahead of its Net Zero Carbon 2040 goal, Sodexo was recently named to CDP’s Climate A List, distinguishing it as the only company in its sector to achieve this environmental leadership rating. Next, we’ll examine how Sodexo’s CDP Climate A List recognition, alongside its broader sustainability commitments, may influence its investment narrative. The...

LVMH Moët Hennessy - Louis Vuitton Société Européenne (ENXTPA:MC) is back in focus after recent trading left the share price near €637.90, inviting investors to reassess the luxury group’s longer term return profile. See our latest analysis for LVMH Moët Hennessy - Louis Vuitton Société Européenne. Recent trading has been slightly softer, with a 1 day share price return of 1.35% and a 7 day share price return of 1.37%. The 1 year total shareholder return of 2.51% contrasts with a 3 year total...

In recent days, L'Oréal S.A. completed a series of euro-denominated bond issues totaling €1.75 billion, including floating-rate notes due 2028 and fixed-rate bonds maturing between 2029 and 2032, to help fund its planned additional 10% stake in Galderma and other corporate purposes. At the same time, L’Oréal’s partnership with iSMART Developments on flexible LED masks and its CES 2026 award-winning beauty tech devices highlight how the group is extending beyond traditional cosmetics into...

Sartorius Stedim Biotech S.A.'s ( EPA:DIM ) price-to-earnings (or "P/E") ratio of 79.2x might make it look like a...

Eramet recently reported strong results in the 2025 Carbon Disclosure Project cycle, securing A- scores for both Climate Change and Water Security as part of its “Act for Positive Mining” CSR roadmap. This recognition underscores Eramet’s progress in sustainable water management, including more reliable data, comprehensive water balances, and alignment with leading international standards. We’ll now examine how Eramet’s stronger CDP scores and environmental credentials may shape the...

As the European markets continue to show optimism with major stock indexes rising, investors are keenly observing opportunities across various sectors. Penny stocks, often seen as a relic of past market eras, still hold potential for growth by offering affordability and the promise of future gains when supported by strong financials. In this article, we spotlight three European penny stocks that exemplify this potential through their robust balance sheets and promising prospects.

Leerink Partners recently initiated coverage on Inventiva with an Outperform rating and a US$12.00 price target, following earlier positive views from UBS and Wolfe Research on the company’s lead NASH/MASH candidate lanifibranor. At the same time, Inventiva secured about US$172.5 million in planned equity financing alongside a US$150 million ADS offering, reinforcing funding for the fully enrolled Phase 3 NATiV3 trial in a disease area that still has no approved therapies. We’ll now examine...

In early January 2026, BrightInsight reported improved adherence and persistence from its Patient App for a key Sanofi–Regeneron biologic, while Sanofi also expanded its immunology footprint through a potential US$2.56 billion-plus autoimmune collaboration with Earendil Labs and advanced Tzield via US priority review in young children and European approval to delay type 1 diabetes progression. These developments highlight how Sanofi is pairing digital tools with regulatory progress in...

As European markets continue to show optimism, with the STOXX Europe 600 Index rising by 2.27% amid a favorable economic backdrop and positive company earnings, investors are exploring various opportunities across the continent. Penny stocks, while often considered a niche area of investment, still offer potential for growth, particularly when these smaller or newer companies demonstrate strong financial health. In this article, we will explore three penny stocks that may combine balance...

In recent weeks, the European market has shown signs of optimism, with the pan-European STOXX Europe 600 Index rising by 2.27%, buoyed by stronger-than-expected industrial production in key economies like Germany and a favorable interest rate environment. As investors navigate this landscape, identifying stocks that demonstrate resilience and growth potential can be crucial, especially those that may not yet have captured widespread attention but are well-positioned to benefit from these...

What ABIVAX Société Anonyme’s recent performance means for investors ABIVAX Société Anonyme (ENXTPA:ABVX) has drawn attention after a period where its share price shows a mix of shorter term softness and stronger past 3 months and 1 year returns, inviting a closer look at fundamentals. See our latest analysis for ABIVAX Société Anonyme. Over the past year, ABIVAX Société Anonyme’s share price has been volatile, with a recent 3 month share price return of 25.6% contrasting with a year to date...

Lumibird's (EPA:LBIRD) stock is up by a considerable 17% over the past three months. However, we decided to pay...

Key Insights Significant control over Métropole Télévision by private companies implies that the general public has...

Robertet's (EPA:RBT) stock up by 9.4% over the past three months. Given that the market rewards strong financials in...

Eurofins Scientific SE ( EPA:ERF ) shareholders would be excited to see that the share price has had a great month...

On 5 January 2026, Capgemini’s Board accepted the resignation of director Megan Clarken and, by co-option, appointed AI specialist Lila Tretikov, Head of AI Strategy at New Enterprise Associates and former Microsoft Corporate Vice President & Deputy CTO. Tretikov’s appointment brings deep Artificial Intelligence and technology-transformation expertise onto Capgemini’s Board, potentially influencing how the group shapes its technology, innovation and governance priorities. We’ll now examine...

Vallourec recently reported trading in its own shares between January 8 and 9, 2026 under its ongoing shareholder-approved buyback program, while also securing a major contract with Shell to supply OCTG products, VAM® premium connections and associated services for the Orca offshore project in Brazil. The Shell Orca award reinforces Vallourec’s role in high-spec offshore tubular solutions and services, highlighting the breadth of its premium value-chain offering in Brazil’s deepwater...

Mercialys (ENXTPA:MERY) is drawing investor attention after recent share price moves, with the stock last closing at €10.64. That price now appears alongside fresh fundamentals data on revenue and earnings. See our latest analysis for Mercialys. Recent trading has been fairly muted, with a 1 day share price return of a 1.66% decline, a 30 day share price return of 1.33% and a year to date share price return close to flat. By contrast, the 1 year total shareholder return of 15.58% and 5 year...

Eutelsat recently awarded Airbus Defence and Space a contract to build 340 additional OneWeb low Earth orbit satellites in Toulouse, while Airbus also reported 793 commercial aircraft deliveries in 2025 and a record backlog of 8,754 planes. This combination of a large, long-dated satellite order and a historically high aircraft backlog underscores how diversified demand is shaping Airbus’s workload. We’ll now explore how this major OneWeb satellite contract, alongside record aircraft...

Planisware SAS (ENXTPA:PLNW) has caught investor attention after recent share price moves, with the stock showing mixed short term returns and a stronger performance over the past 3 months. See our latest analysis for Planisware SAS. The recent pullback in Planisware SAS, with a 1-day share price return of 0.44% decline and a 7-day share price return of 1.72% decline at a €22.85 share price, sits alongside a 30-day share price return of 8.29% and a 90-day share price return of 15.99%. The...

Edenred recently issued a €500 million bond maturing in January 2033 with a 3.75% coupon, attracting demand of over €1.60 billion from international institutional investors and using the proceeds mainly to refinance a bond due in March 2026. This oversubscribed issue extends Edenred’s average bond maturity to 4.1 years and underpins funding for its Amplify25-28 growth plan. Next, we’ll examine how this strongly oversubscribed €500 million bond issue may influence Edenred’s investment...

UBS’s move to downgrade Ipsen (ENXTPA:IPN) to neutral, citing the looming patent expiry of its oncology drug Cabometyx, has pushed the company’s revenue resilience and oncology focus into sharper focus for investors. See our latest analysis for Ipsen. Against UBS’s downgrade, Ipsen’s €129.3 share price sits on the back of an 11.37% year to date share price return. The 5 year total shareholder return of 93.01% points to momentum that has so far been resilient rather than accelerating. If you...